Literature DB >> 12721329

Threonine-205 in the F helix of p450 2B1 contributes to androgen 16 beta-hydroxylation activity and mechanism-based inactivation.

Hsia-Lien Lin1, Haoming Zhang, Lucy Waskell, Paul F Hollenberg.   

Abstract

Four mutants of Thr-205 in cytochrome p450 2B1 were constructed and expressed in Escherichia coli. The Ser-, Ala-, and Val-mutants displayed stable reduced CO difference spectra and were able to metabolize 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, androstenedione, and benzphetamine. The Arg-mutant displayed an unstable reduced CO difference spectrum at 450 nm, was concomitantly converted to a denatured form with a peak at 422 nm, and showed no catalytic activity with any of the four substrates tested. The Ser-mutant displayed activity and metabolite profiles for testosterone and androstenedione similar to those of the wild-type p450 2B1 (WT). Substitution of Thr-205 with Ala or Val markedly suppressed the 16 beta-hydroxylation activity but exhibited little effect on the 16 alpha-hydroxylation activity for testosterone and androstenedione. Because 16 beta-hydroxylation activity of androgens is a specific p450 2B subfamily marker and residue 205 is located in the F helix, which forms the ceiling of the active site, we postulate that the gamma-hydroxyl side chain of Thr may play an important role in directing the 16 beta-face of testosterone and androstenedione toward the active site. Surprisingly, the Val-mutant retained full activity for benzphetamine demethylation. When mechanism-based inactivators for p450 2B1 were used to evaluate the susceptibility to inactivation, the Val-mutant was resistant to inactivation by 17 alpha-ethynylestradiol and less sensitive to inactivation by 2-ethynylnaphthalene compared with the WT enzyme. Our results demonstrate the importance of Thr-205 in determining substrate specificity and product formation as well as in influencing the susceptibility of p450 2B1 to mechanism-based inactivators.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721329     DOI: 10.1124/jpet.103.050260

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1.

Authors:  Haoming Zhang; Cesar Kenaan; Djemel Hamdane; Gaston Hui Bon Hoa; Paul F Hollenberg
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

Review 2.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

3.  Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis.

Authors:  Haoming Zhang; Sean C Gay; Manish Shah; Maryam Foroozesh; Jiawang Liu; Yoichi Osawa; Qinghai Zhang; C David Stout; James R Halpert; Paul F Hollenberg
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

4.  Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Monica Jushchyshyn; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

5.  Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition.

Authors:  Hsia-Lien Lin; Haoming Zhang; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2016-08-18       Impact factor: 3.922

Review 6.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

7.  Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Authors:  Hsia-Lien Lin; Haoming Zhang; Kathleen R Noon; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-08-21       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.